GC-78-HCl is a potent nonpeptide SARS-CoV-2 main protease (Mpro) inhibitor with IC50 of 0.19 uM, exhibits excellent antiviral activity (EC50=0.4 uM).

GC373 is a potent, covalent inhibitor of SARS CoV-2 main protease (MPro) with Kd of 0.15 uM, the reactive aldehyde form of GC376.

GC-14 is a potent, selective and non-covalent non-peptide SARS-CoV-2 main protease (Mpro) inhibitor with IC50 of 0.4 uM, displays excellent selectivity over cathepsins B, F, K, L, and caspase 3 (IC50>50 uM).

DS0464 is a selective, bisubstrate competitive inhibitor SARS-CoV-2 nonstructural protein 14 (nsp14) with IC50 of 1.1 uM, also selective against 28 out of 33 RNA, DNA, and protein MTases.

DMGA is an allosteric and covalent inhibitor of SARS-CoV-2 papain-like protease (SARS-CoV-2 PLpro) with IC50 of 9.4 uM, covalently binds with C270 of the SARS-CoV-2 PLpro.

Difluorobenztropine (AHN 1-055) is a direct-acting SARS-CoV-2 entry inhibitor that targets the SARS-CoV-2 spike fusion peptide domain.

D-4-77 is a potent, covalent peptidyl inhibitor of SARS-CoV-2 main protease (Mpro) with IC50 of 0.95 uM and antiviral EC50 of 0.49 uM.

Cyanorona-20 is a potent and specific SARS-CoV-2 inhibitor with very high selectivity (209- and 45-fold more potent than favipiravir and remdesivir, respectively), effectively binds to and inhibits the SARS-CoV-2 RdRp.

ALG-097111 is a potent and selective SARS-CoV-2 3-chymotrypsin-like cysteine protease (3CLpro) with IC50 of 7 nM, without effect against human cathepsin L (IC50>10 uM).

Acriflavine (Acriflavin) is a topical antiseptic that found to be a potent papain-like protease (PLpro) inhibitor, inhibits SARS-CoV-2 and other betacoronaviruses.

AC1115 is a potent, selective, next-generation antiviral targeting SARS-CoV-2 Mpro and host lysosomal cysteine protease cathepsin L (CTSL) with high antiviral activity, AC1115 is the active form of Olgotrelvir.

AB-00011778 is a small molecule inhibitor of SARS-CoV-2 entry and the Spike/ACE2 interaction, inhibits viral replication with EC50 of 250 nM in A549-ACE2 cells, AB-00011778 is equally effective in impairing the S/ACE2 association in the different mutants.

(S)-chlorcyclizine ((S)-CCZ) is an approved antihistamine drug that is related to dichlorcyclizine (DCCZ), inhibits SARS-CoV and SARS-CoV-2 S-mediated infection in MA104 cells with EC50 of 6.91 and 4.09 uM.

AT-527(Bemnifosbuvir hemisulfate), a hemisulfate salt of AT-511, a guanosine nucleotide prodrug, is a potent and orally active HCV viral replication inhibitor. AT-527 is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC90=0.47 μM). Bemnifosbuvir hemisulfate has pangenotypic antiviral activity[1][2][3].Bemnifosbuvir hemisulfate has pan-genotypic antiviral activities that inhibits HCV genotype 1a (HCV GT1a), HCV GT1b, HCV GT2a, HCV GT3a, HCV GT4a, and HCV GT5a replication with EC50 values of 12.8 nM, 12.5 nM, 9.2 nM, 10.3 nM, 14.7 nM, and 28.5 nM, respectively[1]. In normal human airway epithelial cells, the concentration of Bemnifosbuvir hemisulfate required to inhibit replication of SARS-CoV-2 by EC90 is 0.47 μM, very similar to its EC90 against HCoV-229E, HCoV-OC43 and SARS-CoV in Huh-7 cells[2].When given orally to rats (500 mg/kg) and monkeys (30 mg/kg, 100 mg/kg or 300 mg/kg), Bemnifosbuvir hemisulfate preferentially delivers high levels of AT-9010 in the liver in vivo[1].

AT-273 is the nucleoside metabolite of AT-527.

4'-fluorouridine (4'-FlU, EIDD-2749) is a ribonucleoside analog that inhibits respiratory syncytial virus (RSV), related RNA viruses, and SARS-CoV-2 with high selectivity index (EC50/CC50 of ≥1877) in cells and human airway epithelia organoids. 4'-FlU induces a delayed stalling of RSV and SARS-CoV-2 RdRP (RNA-dependent RNA polymerase).

Proxalutamide (GT-0918) is a nonsteroidal antiandrogen (NSAA) – specifically, a selective high-affinity silent antagonist of the androgen receptor (AR) for the potential treatment of COVID-19, prostate cancer, and breast cancer.

CCF0058981 (CCF981), 3-chlorophenyl analogue, is a noncovalent SARS-CoV-2 3CLpro (SC2) inhibitor with an IC50 of 68 nM. CCF0058981 inhibits SC1 (SARS-CoV-1 3CLpro) with an IC50 of 19 nM. CCF0058981 has antiviral efficacy and has the potential for COVID-19 research.

MM-3122 is a selective inhibitor of host cell serine protease TMPRSS2 (transmembrane protease serine 2) with IC50 of 0.34 nM against recombinant full-length TMPRSS2 protein.

Ensitrelvir (S-217622) fumarate is the first orally active non-covalent, non-peptidic, SARS-CoV-2 3CL protease inhibitor (IC50=13 nM).

PF07321332(nirmatrelvir) is a potent and orally active SARS-CoV 3C-like protease (3CLPRO) inhibitor . PF-07321332 targets to the SARS-CoV-2 virus and can be used for COVID-19 reseacrch.

RAY1216 is an orally active SARS-CoV-2 main protease slow-tight inhibitor with a Ki of 8.6 nM.

MMT5-14 is a remdesivir analogue with a higher antiviral activity in four variants of SARS-CoV-2 than Remdesivir. MMT5-14 inhibits SARS-CoV-2, α, β, γ and δ variants with EC50s of 0.4, 2.5, 15.9, 1.7 and 5.6 μM, respectively. MMT5-14 can be used for the research of COVID-19.

Isomitomycin A is a potential inhibitor against SARS-CoV-2. Isomitomycin A targets to the hACE2 binding site of the modelled surface glycoprotein of SARS-CoV-2. Isomitomycin A can be used in studies of COVID-19.

non-deuterated form of VV116.VV116 is an oral drug candidate of nucleoside analog against SARS-CoV-2.

S-217622 is the first oral non-covalent, non-peptidic SARS-CoV-2 3CL protease inhibitor with IC50 of 0.096 μM. S-217622 displays antiviral activity in vitro towards a range of SARS-CoV-2 variants and coronavirus families, favorable drug metabolism and pha

Remdesivir is a novel RNA-dependent RNA Polymerase,(RdRp) inhibitor. The purity of remdesivir>99.8%,signal impurity<0.05%.

OSELTAMIVIR is an active (orally) inhibitor of the influenze virus neuraminidase and converted to the active acid metabolite in vivo.

GC376 is a novel, first-in-class, small molecule protease inhibitor with a favorable therapeutic index demonstrated in preclinical studies. A common feature of viruses in the picornavirus-like supercluster (including coronaviruses) is a 3C or 3C-like prot

Asapiprant (BGE-175) is a potent and specific antagonist of human PGD2/PTGDR signaling with Ki of 0.44 nM. BGE-175 is currently in a Phase 2 clinical trial to test whether it can prevent disease progression and mortality in older patients hospitalized wit